Bridging the Racial Disparity Gap in Lipid-Lowering Therapy.
作者信息
Kalra Dinesh K
机构信息
Division of Cardiology Rush University Medical Center Lipid Clinic Chicago IL.
出版信息
J Am Heart Assoc. 2021 Jan 5;10(1):e019533. doi: 10.1161/JAHA.120.019533. Epub 2020 Dec 16.
Abstract
摘要
相似文献
1
Bridging the Racial Disparity Gap in Lipid-Lowering Therapy.弥合降脂治疗中的种族差异差距。
J Am Heart Assoc. 2021 Jan 5;10(1):e019533. doi: 10.1161/JAHA.120.019533. Epub 2020 Dec 16.
2
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.抑制前蛋白转化酶枯草溶菌素 9（PCSK9）用玻卡鲁胺对高胆固醇血症患者脂蛋白颗粒的影响。
Clin Ther. 2017 Nov;39(11):2243-2259.e5. doi: 10.1016/j.clinthera.2017.09.009. Epub 2017 Oct 14.
3
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.尽管前蛋白转化酶枯草溶菌素 9 抗体治疗可强力降低低密度脂蛋白胆固醇，但脂蛋白(a)升高的患者仍存在持续性动脉壁炎症。
Eur Heart J. 2019 Sep 1;40(33):2775-2781. doi: 10.1093/eurheartj/ehy862.
4
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.AMG145，一种针对前蛋白转化酶枯草溶菌素 9 的单克隆抗体，可显著降低接受他汀类药物治疗的高胆固醇血症患者的脂蛋白(a)：来自 LDL-C 评估与前蛋白转化酶枯草溶菌素 9 单克隆抗体抑制联合他汀类药物治疗（LAPLACE）-心肌梗死溶栓治疗（TIMI）57 试验的分析。
Circulation. 2013 Aug 27;128(9):962-9. doi: 10.1161/CIRCULATIONAHA.113.001969. Epub 2013 Jul 24.
5
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.一项1期研究，旨在评估RG7652（一种抗前蛋白转化酶枯草溶菌素/9型的全人单克隆抗体）的安全性和降低低密度脂蛋白胆固醇的效果。
Clin Cardiol. 2017 Jul;40(7):503-511. doi: 10.1002/clc.22687. Epub 2017 Mar 22.
6
Lipoprotein(a) Removal Still a Mystery.脂蛋白(a)的清除仍是未解之谜。
J Am Heart Assoc. 2019 Feb 19;8(4):e011903. doi: 10.1161/JAHA.118.011903.
7
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.不同降脂策略后低密度脂蛋白胆固醇、游离前蛋白转化酶枯草溶菌素/克新9型与阿利西尤单抗水平之间的关系
J Am Heart Assoc. 2016 Jun 10;5(6):e003323. doi: 10.1161/JAHA.116.003323.
8
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
9
Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.关于前蛋白转化酶枯草溶菌素 9 单克隆抗体的当代应用的临床指导。
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:52-62. doi: 10.1111/dom.13637.
10
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels.前蛋白转化酶枯草溶菌素 9 抑制剂对血浆神经酰胺水平的影响。
Am J Cardiol. 2020 Aug 1;128:163-167. doi: 10.1016/j.amjcard.2020.04.052. Epub 2020 May 15.
引用本文的文献
1
Striving Towards Equity in Cardiovascular Genomics Research.努力实现心血管基因组学研究的公平性
Curr Atheroscler Rep. 2025 Feb 18;27(1):34. doi: 10.1007/s11883-025-01277-z.
2
Impact of Guideline-Directed Statin Prescriptions on Cardiovascular Outcomes by Race in a Real-World Primary Prevention Cohort.在真实世界的一级预防队列中，指南指导的他汀类药物处方对不同种族心血管结局的影响。
JACC Adv. 2024 Sep 10;3(10):101231. doi: 10.1016/j.jacadv.2024.101231. eCollection 2024 Oct.
3
"I don't think people should die young": perspectives of parents with children diagnosed with familial hypercholesterolemia.“我认为人们不该英年早逝”：子女被诊断为家族性高胆固醇血症的家长们的观点
J Community Genet. 2024 Oct;15(5):549-558. doi: 10.1007/s12687-024-00725-8. Epub 2024 Aug 10.
4
The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias.血脂异常管理中获取新兴疗法的障碍及潜在解决方案
J Clin Med. 2024 Jul 16;13(14):4160. doi: 10.3390/jcm13144160.
5
Estimating the Prevalence of Hypercholesterolemia in Indigenous Populations: A Systematic Review and Meta-Analysis.估算原住民人群中高胆固醇血症的患病率：一项系统评价与荟萃分析
JACC Adv. 2023 May 26;2(3):100315. doi: 10.1016/j.jacadv.2023.100315. eCollection 2023 May.
6
Unique features of dyslipidemia in women across a lifetime and a tailored approach to management.女性一生中血脂异常的独特特征及个性化管理方法。
Am J Prev Cardiol. 2024 Apr 5;18:100666. doi: 10.1016/j.ajpc.2024.100666. eCollection 2024 Jun.
7
An Appraisal of the Preventive Effect of Statins on the Development of Graves' Ophthalmopathy: A Hospital-Based Cohort Study.他汀类药物对格雷夫斯眼病发生的预防作用评估：一项基于医院的队列研究。
Ophthalmol Ther. 2024 Jun;13(6):1499-1511. doi: 10.1007/s40123-024-00930-1. Epub 2024 Apr 6.
8
Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients.乳腺癌患者蒽环类药物所致心脏毒性的种族差异
Biomedicines. 2023 Aug 17;11(8):2286. doi: 10.3390/biomedicines11082286.
9
Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population.塔伏雷西单抗是一种新型的PCSK9单克隆抗体，在中国人群中值得期待。
JACC Asia. 2023 Jul 11;3(4):646-648. doi: 10.1016/j.jacasi.2023.06.002. eCollection 2023 Aug.
10
The evolving landscape of PCSK9 inhibition in cancer.PCSK9 抑制在癌症中的不断演变的格局。
Eur J Pharmacol. 2023 Jun 15;949:175721. doi: 10.1016/j.ejphar.2023.175721. Epub 2023 Apr 12.
本文引用的文献
1
Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.依洛尤单抗对不同种族和民族的低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇、载脂蛋白 B 和脂蛋白(a)的影响：来自双盲和开放标签延伸研究的个体参与者数据的荟萃分析。
J Am Heart Assoc. 2021 Jan 5;10(1):e016839. doi: 10.1161/JAHA.120.016839. Epub 2020 Dec 16.
2
Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation.在美国，种族或民族与女性他汀类药物的使用不足有关吗：全美女性健康研究。
Clin Cardiol. 2020 Dec;43(12):1388-1397. doi: 10.1002/clc.23448. Epub 2020 Aug 30.
3
PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability.非裔美国人和高加索人中的前蛋白转化酶枯草溶菌素9与脂蛋白(a)水平、载脂蛋白(a)大小及遗传度的关系
J Endocr Soc. 2020 Jun 11;4(7):bvaa073. doi: 10.1210/jendso/bvaa073. eCollection 2020 Jul 1.
4
Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.支持近期美国食品和药物管理局批准新型心血管代谢药物的关键试验中女性和少数族裔入组的十年趋势。
J Am Heart Assoc. 2020 Jun 2;9(11):e015594. doi: 10.1161/JAHA.119.015594. Epub 2020 May 19.
5
Heterogeneity of Treatment and Outcomes Among Asians With Coronary Artery Disease in the United States.美国亚裔冠心病患者的治疗与结局的异质性。
J Am Heart Assoc. 2020 May 18;9(10):e014362. doi: 10.1161/JAHA.119.014362. Epub 2020 May 11.
6
JCL roundtable: South Asian atherosclerotic risk.《临床化学杂志》圆桌会议：南亚地区的动脉粥样硬化风险
J Clin Lipidol. 2020 Mar-Apr;14(2):161-169. doi: 10.1016/j.jacl.2020.03.005.
7
Low-density lipoprotein cholesterol goals in the secondary prevention of cardiovascular diseases in the Indian population-Is 30 the new 70?印度人群心血管疾病二级预防中的低密度脂蛋白胆固醇目标——30会成为新的70吗？
J Clin Lipidol. 2020 Mar-Apr;14(2):173-175. doi: 10.1016/j.jacl.2020.01.011. Epub 2020 Jan 30.
8
Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System.种族对大型医疗体系中具有高动脉粥样硬化性心血管疾病风险的患者进行他汀类药物一级预防的影响。
J Am Heart Assoc. 2019 Nov 19;8(22):e014709. doi: 10.1161/JAHA.119.014709. Epub 2019 Nov 11.
9
Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials.依洛尤单抗疗效和安全性的种族和民族差异：来自 3 项 ODYSSEY 阶段 3 试验的分析。
J Clin Lipidol. 2019 Jul-Aug;13(4):586-593.e5. doi: 10.1016/j.jacl.2019.06.002. Epub 2019 Jun 27.
10
Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations.在白种人和亚洲人群中，依洛尤单抗的药代动力学和药效学无种族差异。
Br J Clin Pharmacol. 2019 Jan;85(1):114-125. doi: 10.1111/bcp.13767. Epub 2018 Oct 17.
Zotero 插件